Precipio, Inc. (PRPO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, operating CLIA-certified laboratories in New Haven, Connecticut, and Omaha, Nebraska. The company develops diagnostic products and services to address cancer misdiagnoses. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $5.65 million | $10.58 million | $4.44 million | $7.87 million |
| Gross Profit | $2.43 million | $4.57 million | $1.72 million | $2.64 million |
| Gross Margin | 43% | 43% | 39% | 34% |
| Operating Loss | $(0.82) million | $(1.68) million | $(1.21) million | $(3.28) million |
| Net Income (Loss) | $0.07 million | $(0.81) million | $(1.22) million | $(3.30) million |
| Cash and Equivalents | $1.13 million (as of June 30, 2025) | |||
| Working Capital | $(0.30) million (Deficit) | |||
| Accumulated Deficit | $(103.25) million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 27% in Q2 2025 and 34% YTD compared to 2024, driven by a 19% increase in diagnostic cases processed (3,692 cases in Q2 2025 vs. 3,099 in Q2 2024).
- Profitability: The company reported a net income of $74,000 in Q2 2025, a significant turnaround from a net loss of $1.22 million in the same period last year. This was primarily due to non-recurring items.
- Unusual Items: Q2 2025 results included $0.79 million in Employee Retention Credit (ERC) income and a $0.14 million gain on the settlement of a liability. Excluding these, the company would have reported a net loss.
- Cost Structure: Cost of sales increased due to higher case volume, but gross margins improved due to economies of scale.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for the next 12 months. This is due to an accumulated deficit of $103.3 million and a working capital deficit of $0.3 million. Continued operations depend on raising additional financing and achieving business plan targets.
- Liquidity: The company has an "At the Market" (ATM) sales agreement with approximately $3.7 million remaining availability. In July 2025 (subsequent event), the company raised approximately $1.3 million from warrant exercises.
- Change Healthcare (CHC) Impact: The company is repaying a $0.6 million balance from CHC's Temporary Funding Assistance Program (related to the 2024 cyberattack) through January 2026. A $0.1 million portion was written off in Q2 2025.
- Regulatory Risk: The "One Big Beautiful Bill Act" (OBBBA) was enacted on July 4, 2025, introducing changes to federal tax law that may impact the company's effective tax rate and R&D expense treatment.
- Legal Proceedings: The company is involved in a lawsuit from a former employee alleging unfair dismissal and has delinquent accounts payable with certain vendors.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.13 million cash balance plus the $1.3 million subsequent warrant proceeds against the $0.3 million working capital deficit and upcoming debt/lease obligations.
- Recurring vs. Non-Recurring Income: Confirm the sustainability of operations without the $0.79 million ERC credit and $0.14 million liability settlement gain included in Q2 2025 net income.
- CHC Repayment Schedule: Monitor the impact of the $83,000 monthly repayments to Change Healthcare on future cash flows.
- ATM Utilization: Track the utilization of the remaining $3.7 million under the AGP sales agreement to fund operations.
- Customer Concentration: Note that one customer (Customer C) accounted for 27% of net sales and 25% of accounts receivable in the six months ended June 30, 2025.